First Tracks Biotherapeutics, Inc. (TRAX)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
36.04 USD
+1.91
(5.596%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 35.50 -0.54 (-0.540%) ⇩ (Oct. 15, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:06 a.m. EDT
The immediate outlook is murky, defined by a stark divergence between defensive hedging and speculative long bets. While the recent price action shows a downward drift from the 41 peak to the current 31.85 level, the heavy put open interest suggests the market is bracing for further weakness. However, the presence of new call volume at strikes significantly above the current price hints at a belief in a potential catalyst-driven rebound. Fundamentally, the picture is precarious: the company is burning cash with negative operating cash flow and negative earnings, relying entirely on a successful spin-off to validate its existence. The balance sheet is technically strong due to the cash infusion from the separation, but without proven revenue or profitability, the business remains a high-risk venture. The lack of a dividend is expected for a pre-revenue biotech, but the absence of consistent growth metrics prevents any long-term bullish thesis from taking root. Investors are currently caught between the safety of the cash-rich post-spin entity and the risk of a failed clinical program. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.071859 |
| AutoARIMA | 0.071859 |
| MSTL | 0.072704 |
| AutoTheta | 0.104539 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 2.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.255 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.567 |
| Market Cap | 1,287,739,648 |
| Forward P/E | -10.06 |
| Website | https://www.firsttracksbio.com |
As of Oct. 10, 2026, 7:06 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts (strikes 15, 25, 30) across multiple expirations, suggesting a fear of further downside or a 'crash' scenario. Conversely, there is notable new volume flowing into out-of-the-money calls (strikes 50, 55) and significant open interest in deep in-the-money calls (strike 15), indicating a split sentiment where some traders are betting on a massive recovery while others are hedging against continued volatility. The implied volatility remains elevated, reflecting uncertainty rather than a clear directional consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7963158 |
| Address1 | 10,770 Wateridge Circle |
| Address2 | Suite 210 |
| All Time High | 49.91 |
| All Time Low | 14.72 |
| Ask | 43.84 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,511,230 |
| Average Daily Volume3 Month | 830,828 |
| Average Volume | 830,828 |
| Average Volume10Days | 1,511,230 |
| Bid | 26.06 |
| Bid Size | 2 |
| Book Value | 4.77 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 36.04 |
| Current Ratio | 14.28 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 36.3 |
| Day Low | 33.985 |
| Debt To Equity | 2.567 |
| Display Name | First Tracks Biotherapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -169,075,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.648 |
| Enterprise Value | 1,124,054,528 |
| Eps Current Year | -4.03538 |
| Eps Forward | -3.58351 |
| Eps Trailing Twelve Months | -4.71 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 39.6882 |
| Fifty Day Average Change | -3.648201 |
| Fifty Day Average Change Percent | -0.091921546 |
| Fifty Two Week Change Percent | 79.63158 |
| Fifty Two Week High | 49.91 |
| Fifty Two Week High Change | -13.869999 |
| Fifty Two Week High Change Percent | -0.2779002 |
| Fifty Two Week Low | 14.72 |
| Fifty Two Week Low Change | 21.32 |
| Fifty Two Week Low Change Percent | 1.4483695 |
| Fifty Two Week Range | 14.72 - 49.91 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,775,482,200,000 |
| Float Shares | 26,150,332 |
| Forward Eps | -3.58351 |
| Forward P E | -10.057179 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 104 |
| Fullday Change | 1.3699989 |
| Fullday Change Percent | 4.0140605 |
| Fullday Price | 36.04 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.087469995 |
| Held Percent Institutions | 1.00792 |
| Implied Shares Outstanding | 35,730,843 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California. |
| Long Name | First Tracks Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,287,739,648 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1964321808 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -160,304,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,309,892,704 |
| Number Of Analyst Opinions | 12 |
| Open | 34.26 |
| Operating Cashflow | -123,762,000 |
| Operating Margins | 0.0 |
| Phone | 858 362 6295 |
| Post Market Change | -0.5400009 |
| Post Market Change Percent | -1.4983376 |
| Post Market Price | 35.5 |
| Post Market Time | 1,792,107,008 |
| Previous Close | 34.13 |
| Price Eps Current Year | -8.9310055 |
| Price Hint | 2 |
| Price To Book | 7.555556 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.906 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 1.91 |
| Regular Market Change Percent | 5.59625 |
| Regular Market Day High | 36.3 |
| Regular Market Day Low | 33.985 |
| Regular Market Day Range | 33.985 - 36.3 |
| Regular Market Open | 34.26 |
| Regular Market Previous Close | 34.13 |
| Regular Market Price | 36.04 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 1,578,446 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 35,730,843 |
| Shares Percent Shares Out | 0.1453 |
| Shares Short | 5,190,809 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,030,463 |
| Short Name | First Tracks Biotherapeutics, I |
| Short Ratio | 7.05 |
| Source Interval | 15 |
| State | CA |
| Symbol | TRAX |
| Target High Price | 100.0 |
| Target Low Price | 57.0 |
| Target Mean Price | 72.5 |
| Target Median Price | 70.0 |
| Total Cash | 168,018,000 |
| Total Cash Per Share | 4.702 |
| Total Debt | 4,333,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.71 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.497389 |
| Two Hundred Day Average Change | 6.542612 |
| Two Hundred Day Average Change Percent | 0.2218031 |
| Type Disp | Equity |
| Volume | 1,578,446 |
| Website | https://www.firsttracksbio.com |
| Zip | 92,121 |